What Is Semax?
Semax is a synthetic peptide made from seven amino acids. It was designed from a short part of adrenocorticotropic hormone, a natural hormone normally shortened to ACTH. Semax was altered so that it does not reproduce ACTH's main hormone effect.
Researchers have studied Semax mainly for possible protective effects in the brain, including recovery after an ischaemic stroke. An ischaemic stroke happens when a blood clot blocks blood flow to part of the brain. Semax is used as a medicine in Russia, but it is not approved by the US Food and Drug Administration (FDA), which regulates medicines in the United States, or authorised by the European Medicines Agency (EMA), which assesses medicines for the European Union.
What is Semax made from?
Semax has the amino-acid sequence methionine, glutamic acid, histidine, phenylalanine, proline, glycine and proline. An amino acid is a small building block used to make peptides and proteins.
The first four amino acids come from positions 4 to 7 of ACTH. ACTH is produced by the pituitary gland, a small gland beneath the brain, and normally tells the adrenal glands, which sit above the kidneys, to release cortisol. Cortisol helps regulate the body's response to stress and affects metabolism and immune activity.
Researchers attached the sequence proline-glycine-proline to the ACTH fragment. This addition was intended to make the peptide more stable while avoiding the main adrenal-stimulating activity of the complete hormone.
For this reason, Semax is described as an ACTH analogue. An analogue is a molecule designed to resemble part of another molecule while changing some of its properties.
What did Health Canada's November 2026 peptide contamination warning find?
On 12 November 2026, Health Canada reported that laboratory testing had identified *Sphingomonas aquatilis/melonis* bacteria in an injectable peptide product seized from a retailer in Ottawa. The retailer's unauthorised inventory included products labelled Semax. The agency did not say that every product on its inventory list, or every batch of the named compound, tested positive for bacteria.
This is a product-quality and safety finding, not a new clinical trial of the peptide. Bacterial contamination in material intended for injection can cause serious infection, including sepsis. The agency also warned that a label saying 'for research use only' does not demonstrate sterility or make an unauthorised product suitable for human use. The finding cannot be used to estimate contamination rates across the wider market or to judge the quality of material used in controlled clinical studies.
Is Semax a nootropic?
Semax is often called a nootropic. A nootropic is a substance claimed to improve thinking, memory, attention or other mental performance.
That label describes the purpose for which a substance is promoted, not the quality of evidence behind it. Research showing a change in brain-cell signalling or an animal's behaviour does not show that it improves thinking or memory in healthy people.
Human research on Semax has focused more heavily on neurological illness, particularly stroke, than on enhancement of healthy adults. There is not a strong collection of large, independently replicated trials showing better memory or concentration in healthy users.
How might Semax affect the brain?
The exact mechanism is not settled. A mechanism is the biological process through which a substance may produce an effect.
Much of the research concerns brain-derived neurotrophic factor, normally shortened to BDNF. BDNF is a protein that helps nerve cells survive, form connections and adapt. This ability of the brain to change its connections is called neuroplasticity.
Studies in animals and laboratory-grown cells have found changes in BDNF and tropomyosin receptor kinase B, shortened to TrkB. TrkB is a receptor, which means it is a protein that receives a biological signal and changes how a cell behaves. Researchers have also reported changes in gene expression, meaning which genetic instructions cells make more or less active, including genes involved in blood-vessel function, immune signalling and responses to reduced oxygen.
Semax may also influence dopamine and serotonin systems. Dopamine and serotonin are neurotransmitters, chemicals used by nerve cells to communicate. These findings do not provide a complete explanation, and they do not show that every laboratory change is helpful in a person.
What is neuroprotection?
Neuroprotection means protecting nerve cells from damage or death. It is a useful research aim after stroke, traumatic injury and diseases that gradually damage the nervous system.
The word is easily overused. A substance may appear neuroprotective in cells or an animal model without improving disability, independence or survival in patients. For Semax, the central question is not only whether a laboratory measurement changes, but whether people recover better and whether the treatment is acceptably safe.
What human stroke research exists?
Several studies from Russia have investigated Semax during recovery from ischaemic stroke. The publications report possible improvements in recovery of brain and nervous-system function, as well as changes in biological measurements. However, important details are not always available in the English-language abstracts.
A 1997 comparative study included 30 people in the acute period after a moderate or severe ischaemic stroke. “Acute” means the early period shortly after the stroke. They received Semax in addition to intensive standard care. The comparison group contained 80 people with strokes described as similar in severity and location who received conventional treatment without Semax.
The researchers used rating scales to assess the severity of the stroke and recovery of functions such as movement. They also measured electrical activity and responses in the brain. The report described faster recovery in some Semax groups, particularly for movement problems. The treatment course lasted five days for moderate stroke and ten days for severe stroke.
The English abstract does not say that people were assigned to the two groups by chance or that participants and assessors were kept unaware of treatment. Assignment by chance, called randomisation, helps make comparison groups more similar at the start. Keeping participants or assessors unaware of treatment, called masking, helps reduce the effect of expectations on results. The unequal group sizes and limited reporting also make the findings harder to assess by modern trial standards.
A separate 1999 report looked back at clinical and laboratory information from acute stroke treatment. This is called a retrospective analysis. It examined inflammatory signals and other measurements linked with brain injury, but the English abstract does not provide enough detail to establish that changes in those measurements improved patients' recovery.
The reported administration levels were 12 milligrams per day for moderate stroke and 18 milligrams per day for severe stroke in the 1997 study protocol. A milligram is one-thousandth of a gram. These are historical research levels from a clinical setting, not instructions for personal use.
What did the 2018 rehabilitation study find?
A 2018 study followed 110 people for five months at different stages after an ischaemic stroke. It examined Semax alongside rehabilitation, which is structured therapy intended to help someone regain movement, speech or everyday abilities after illness or injury. Participants were divided into earlier and later rehabilitation groups, and each group included people who did and did not receive Semax.
The researchers measured motor performance, meaning control of physical movement, and used the Barthel Index, a score of how independently someone can manage everyday activities. They also measured BDNF in blood plasma, the liquid part of blood. They reported that Semax was associated with higher BDNF measurements and that higher BDNF measurements were associated with faster functional recovery.
The available abstract does not say that treatment was assigned by chance or that participants and assessors were unaware of the groups. It also does not provide enough detail to judge every part of the study as confidently as a full modern trial report. The study cannot show that Semax alone caused the reported recovery or that raising BDNF would improve recovery in another group of patients.
This is supportive but limited evidence, not proof that Semax is an established stroke treatment in health systems outside Russia.
Has Semax been studied in healthy people?
A small brain-imaging study included 24 healthy adults. Fourteen received intranasal Semax and ten received a placebo. Intranasal means applied inside the nose. A placebo is an inactive comparison designed to resemble the study treatment.
Researchers used resting-state functional magnetic resonance imaging, shortened to fMRI. This type of scan measures changes related to blood flow while a person is not carrying out a set task. Researchers use it to study patterns of brain activity. Scans were performed before the study treatment and five and twenty minutes afterwards.
The study reported short-term changes in connections within the brain's default mode network. This network is a group of brain regions that tend to be active during internally focused thought.
The study was small and measured brain-imaging signals, not meaningful improvements in memory, work performance or everyday function. A scan change is not the same as a clinical benefit.
What do animal studies add?
Animal studies allow researchers to examine brain tissue and gene activity in ways that are not normally possible in people. Semax has been studied in rodents, meaning rats and mice, used as models of stroke, stress, memory and diseases that gradually damage nerve cells.
A model recreates selected features of a human condition in an animal. For example, researchers may temporarily block an artery in a rat to study the effects of reduced blood flow in the brain. The model can reveal a possible mechanism, but it does not reproduce the full human disease.
Recent work has continued to examine Semax and related peptides in mouse models of Alzheimer's disease. Alzheimer's disease progressively damages memory and thinking. Improvements in a mouse task do not show that Semax treats Alzheimer's disease in people.
Animal findings are best understood as reasons to conduct better human trials, not as substitutes for them.
How strong is the clinical evidence?
The evidence is stronger than a claim based only on cells or animals because Semax has been given to human participants. It is still weaker than the evidence normally expected for approval by major international regulators.
There is no clear sequence of widely accessible Phase 1, Phase 2 and Phase 3 publications. Phase 1 usually examines initial safety and how the body handles a medicine. Phase 2 asks whether it appears to work in people with the target condition and records common side effects. Phase 3 normally uses larger groups to confirm benefits and gather more safety evidence before a possible approval application.
Many Semax publications use small groups, provide limited English-language detail or come from connected Russian research teams. Independent replication means a separate research group repeats a study and finds a similar result. More independent, well-reported research would make the conclusions more dependable. The Orentra Research Methodology explains how these features affect the strength of evidence.
Is Semax approved?
Semax is described in Russian medical literature as an approved and marketed medicine in Russia for certain neurological uses. Russia has its own regulatory system and clinical practice.
Semax is not approved by the FDA or authorised by the EMA.
Approval in one country does not automatically transfer to another. Each regulator considers the product, manufacturing controls, evidence, proposed uses and safety information under its own rules.
There is no FDA-approved or EMA-authorised Semax product for stroke, memory, attention, anxiety, depression or general cognitive enhancement.
What benefits are claimed, and what does the evidence show?
| Claim | What the evidence supports |
|---|---|
| Helps stroke recovery | Limited Russian human studies report possible benefits, but stronger independent and fully reported trials are needed |
| Raises BDNF | Changes have been measured in animal research and a human stroke study; the clinical meaning is uncertain |
| Improves memory or focus | Animal research and small human studies do not establish a dependable benefit in healthy people |
| Reduces anxiety or depression | Mainly supported by animal findings, not adequate treatment trials in people |
| Protects the brain | Biological and animal evidence is plausible, but the term does not establish improved patient outcomes |
| Treats Alzheimer's disease | No adequate human trial establishes this use |
What is known about side effects?
The available clinical literature does not provide the complete, easily assessed safety database expected for an FDA-approved or EMA-authorised medicine.
Russian product information and secondary reports describe local nasal irritation and other short-term reactions, but reporting varies. Small studies may miss uncommon effects, interactions and problems that appear after repeated or long-term exposure.
Semax was derived from part of ACTH but was designed not to reproduce its main cortisol-releasing action. That design does not prove that the peptide has no hormonal or wider biological effects.
Products bought online add separate risks. The name on a bottle does not confirm that it contains the stated substance or amount, is free from unwanted contaminants or bacteria, or will remain unchanged during its stated shelf life.
Is Semax the same as ACTH?
No. ACTH is a 39-amino-acid hormone that stimulates cortisol release from the adrenal glands. Semax is a seven-amino-acid analogue built from a short ACTH fragment plus a stabilising tail.
Semax was intended to retain possible nervous-system activity without acting like the complete hormone. Findings about ACTH cannot automatically be applied to Semax, and findings about Semax do not describe the full hormone.
How does Semax compare with Selank?
Both are Russian-developed peptides promoted for effects on the brain, but they have different structures and research histories.
Semax was derived from an ACTH fragment and has been studied mainly in stroke and experimental brain-injury research. Selank was developed from a fragment associated with the immune system and is discussed more often in anxiety research.
There is no strong clinical trial comparing them directly, so the evidence does not show that one is better. This article does not recommend combining them.
Frequently asked questions
Is Semax a peptide?
Yes. It is a synthetic chain of seven amino acids, which makes it a heptapeptide, the scientific term for a peptide with seven amino acids.
Is Semax a steroid?
No. It was designed from a fragment of ACTH, a peptide hormone, but Semax is not a steroid and does not reproduce the full hormone's main action.
Does Semax increase BDNF?
Animal studies and some human stroke research report changes in BDNF. It remains unclear whether this creates a dependable benefit in healthy people.
Does Semax improve memory?
There is not enough high-quality human evidence to establish a meaningful memory benefit.
Is Semax approved in the United States?
No. It has no FDA-approved medical use.
Why is Semax applied through the nose in studies?
Researchers have used the nasal route as a way to deliver the peptide without swallowing it. This article reports that research context but does not provide administration instructions.
Is Semax safe?
Its complete safety profile has not been established to the standard expected for approval in the United States or European Union.
Can Semax be combined with Selank?
This guide provides no advice about combining peptides, sometimes called stacking. Adequate human research with a comparison group has not established the benefit or safety of that combination.
What the evidence supports today
Semax has been studied in laboratory-grown cells, animals and people. The human evidence comes mainly from Russian stroke research, while most claims about memory, focus, mood and healthy-person performance rely on laboratory, animal or very small human studies.
The evidence still has major limits. Much of the clinical reporting is difficult to assess fully, independent international replication is limited, and there is no FDA or EMA approval. Claims about healthy-person memory, focus, mood and performance extend beyond what human studies have established.
The human stroke findings are preliminary. Important questions about clinical benefit, long-term safety and whether results would be repeated by independent research groups remain unresolved outside its existing national use.
Sources
Research reviewed through 17 November 2026.